A new partnership spurs innovation at CellCeuticals.

With the trend toward avoiding the knife and treating skin on a cellular level, Histogen Aesthetics, a subsidiary of regenerative medicine company Histogen, Inc., focused on skin care and cosmeceuticals, has acquired the CellCeuticals Biomedical Skin Treatments line of skin care products.

 Histogen Aesthetics will continue sales of the 11 existing CellCeuticals Biomedical Skin Treatments skin care products, while bringing new innovation to the line through the addition of what it calls “a unique regenerative medicine technology, working to improve skin aging at a cellular level.”

  Dr. Naughton has spent more than 30 years in tissue engineering and regenerative medicine, and holds over 100 patents in the field. She founded Histogen in 2007, focused on developing therapies that work to stimulate the stem cells in the body to regenerate tissues and organs.

The CellCeuticals system is comprised of 11 distinctive products.